Health Care Up as Novo Nordisk, Hims & Hers Settle Dispute -- Health Care Roundup

Dow Jones

03/10

Health-care companies rose as a distribution spat was resolved.

Wegovy maker Novo Nordisk said it was teaming up with Hims & Hers Health to sell its weight-loss drugs through the telehealth company's platform, bringing an end to a legal dispute between the two companies. Shares of Hims & Hers jumped, logging their largest percentage gains on record.

Vaccine makers rose after the Food and Drug Administration's controversial vaccines chief, Dr. Vinay Prasad, stepped down.

British drug giant GSK said it would sell rights to linerixibat, an experimental treatment for itching caused by a liver disease, to Italian pharmaceutical company Alfasigma as part of a licensing agreement valued at up to $690 million.

Write to Rob Curran at rob.curran@dowjones.com

(END) Dow Jones Newswires

March 09, 2026 17:43 ET (21:43 GMT)

应版权方要求，你需要登录查看该内容

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2618708726"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2618708726\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2618708726?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-10 05:43","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2618708726","market":"nz","top_or_hot":-1,"title":"Health Care Up as Novo Nordisk, Hims & Hers Settle Dispute -- Health Care Roundup","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  Health-care companies rose as a distribution spat was resolved. \n</p>\n<p>\n  Wegovy maker <a href=\"https://laohu8.com/S/NVO\">Novo Nordisk</a> said it was teaming up with Hims &amp; Hers Health to sell its weight-loss drugs through the telehealth company's platform, bringing an end to a legal dispute between the two companies. Shares of Hims &amp; Hers jumped, logging their largest percentage gains on record. \n</p>\n<p>\n  Vaccine makers rose after the Food and Drug Administration's controversial vaccines chief, Dr. Vinay Prasad, stepped down. \n</p>\n<p>\n  British drug giant GSK said it would sell rights to linerixibat, an experimental treatment for itching caused by a liver disease, to Italian pharmaceutical company Alfasigma as part of a licensing agreement valued at up to $690 million. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Rob Curran at rob.curran@dowjones.com \n</p>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  March 09, 2026 17:43 ET (21:43 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Health Care Up as Novo Nordisk, Hims & Hers Settle Dispute -- Health Care Roundup</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHealth Care Up as Novo Nordisk, Hims & Hers Settle Dispute -- Health Care Roundup\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-03-10 05:43</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  Health-care companies rose as a distribution spat was resolved. \n</p>\n<p>\n  Wegovy maker <a href=\"https://laohu8.com/S/NVO\">Novo Nordisk</a> said it was teaming up with Hims &amp; Hers Health to sell its weight-loss drugs through the telehealth company's platform, bringing an end to a legal dispute between the two companies. Shares of Hims &amp; Hers jumped, logging their largest percentage gains on record. \n</p>\n<p>\n  Vaccine makers rose after the Food and Drug Administration's controversial vaccines chief, Dr. Vinay Prasad, stepped down. \n</p>\n<p>\n  British drug giant GSK said it would sell rights to linerixibat, an experimental treatment for itching caused by a liver disease, to Italian pharmaceutical company Alfasigma as part of a licensing agreement valued at up to $690 million. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Rob Curran at rob.curran@dowjones.com \n</p>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  March 09, 2026 17:43 ET (21:43 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4599","symbol_name":"减肥药","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2618708726","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2618708726","pubTimestamp":1773092580,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Health-care companies rose as a distribution spat was resolved.Wegovy maker Novo Nordisk said it was teaming up with Hims & Hers Health to sell its weight-loss drugs through the telehealth company's platform, bringing an end to a legal dispute between the two companies. Shares of Hims & Hers jumped, logging their largest percentage gains on record.Vaccine makers rose after the Food and Drug Administration's controversial vaccines chief, Dr. Vinay Prasad, stepped down.British drug giant GSK said it would sell rights to linerixibat, an experimental treatment for itching caused by a liver disease, to Italian pharmaceutical company Alfasigma as part of a licensing agreement valued at up to $690 million.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4599":"减肥药","HIMS":"Hims & Hers Health Inc.","LU1093756325.SGD":"FTIF - Franklin K2 Alt Strat Fd A (acc) SGD-H1","LU0154236417.USD":"BGF US FLEXIBLE EQUITY \"A2\" ACC","BK4007":"制药","NVOH":"Novo Nordisk A/S B Shares ADRhedged","BK4581":"高盛持仓","NVO":"诺和诺德","XBI":"SPDR S&P Biotech ETF","LU1093756168.USD":"FRANKLIN K2 ALTERNATIVE STRATEGIES \"A\" (USD) ACC","BK4588":"碎股","NVOX":"2倍做多NVO ETF-Defiance","IE00BKVL7J92.USD":"Legg Mason ClearBridge - US Equity Sustainability Leaders A Acc USD","LABU":"三倍做多标普生物-Direxion","BK4585":"ETF&股票定投概念","IE00BZ1G4Q59.USD":"LEGG MASON CLEARBRIDGE US EQUITY SUSTAINABILITY LEADER \"A\"(USD) INC (A)","BK4532":"文艺复兴科技持仓"},"translate_title":"诺和诺德、Hims&Hers解决纠纷，医疗保健崛起——医疗保健综述","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"HIMS":1.91,"NVOH":0.6,"XBI":0.6,"NVOX":0.6,"LABU":0.6,"NVO":1.93},"content_text":"Health-care companies rose as a distribution spat was resolved. \n\n\n  Wegovy maker Novo Nordisk said it was teaming up with Hims & Hers Health to sell its weight-loss drugs through the telehealth company's platform, bringing an end to a legal dispute between the two companies. Shares of Hims & Hers jumped, logging their largest percentage gains on record. \n\n\n  Vaccine makers rose after the Food and Drug Administration's controversial vaccines chief, Dr. Vinay Prasad, stepped down. \n\n\n  British drug giant GSK said it would sell rights to linerixibat, an experimental treatment for itching caused by a liver disease, to Italian pharmaceutical company Alfasigma as part of a licensing agreement valued at up to $690 million. \n\n\n \n\n\n  Write to Rob Curran at rob.curran@dowjones.com \n\n\n  (END) Dow Jones Newswires\n\n\n  March 09, 2026 17:43 ET (21:43 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}